pargyline has been researched along with Benign Neoplasms, Brain in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sareddy, GR | 1 |
| Nair, BC | 1 |
| Krishnan, SK | 1 |
| Gonugunta, VK | 1 |
| Zhang, QG | 1 |
| Suzuki, T | 1 |
| Miyata, N | 1 |
| Brenner, AJ | 1 |
| Brann, DW | 1 |
| Vadlamudi, RK | 1 |
| Marcozzi, G | 1 |
| Befani, O | 1 |
| Mondovì, B | 1 |
2 other studies available for pargyline and Benign Neoplasms, Brain
| Article | Year |
|---|---|
KDM1 is a novel therapeutic target for the treatment of gliomas.
Topics: Animals; Apoptosis Regulatory Proteins; Benzamides; Blotting, Western; Brain Neoplasms; Cell Line, T | 2013 |
Type B monoamine oxidase activity in human brain malignant tumors.
Topics: Animals; Blood Platelets; Brain Neoplasms; Female; Guanidines; Humans; Male; Mitochondria; Monoamine | 1998 |